Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 in MCI or Mild Dementia Due to Alzheimer's Disease
NCT07741526Phase 2Active, not recruiting
- Sponsor
- Arctic Therapeutics
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Countries
- 2
01
Overview
A Phase 2 trial of N-acetylcysteine amide in Alzheimer's disease (AD), sponsored by Arctic Therapeutics. Started Oct 2025; status: active, not recruiting.
02
Drugs
N-acetylcysteine amide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07741526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741526.